Focusing on the future biotechnology (biopharmaceutical) industry, Yin Hong invites company representatives, experts, and scholars for face-to-face exchanges.

Yin Hong Presides Over Future Biotechnology (Biopharmaceuticals) Industry Development Forum, Emphasizing

Fully Leveraging Comparative Advantages to Focus on Niche Segments

Adapting to Local Conditions to Promote High-Quality Development of the Biopharmaceutical Industry

On March 31, Secretary of the Provincial Party Committee Yin Hong presided over the Future Biotechnology (Biopharmaceuticals) Industry Development Forum, inviting representatives from some enterprises and experts and scholars for face-to-face exchanges. Yin Hong emphasized the need to thoroughly implement the spirit of the Fourth Plenary Session of the 20th CPC Central Committee, proactively align with national strategic needs, accurately grasp industry development trends, base efforts on our own strengths, learn from others’ advantages, fully leverage comparative advantages, focus on tackling niche segments, and adapt to local conditions to promote the high-quality development of our province’s biopharmaceutical industry, providing strong support for writing a new chapter of Chinese-style modernization in Jiangxi.

Provincial leaders Chen Min, Xia Wenyong, and Shi Ke attended.

“The ‘14th Five-Year’ Plan proposal clearly designates the biopharmaceutical industry as an emerging pillar industry, and it has been incorporated into the ‘14th Five-Year’ Plan outline and the State Council’s government work report, further highlighting the strategic position of the biopharmaceutical industry. The ‘6+N’ future industry tracks laid out by the Provincial Party Committee and Provincial Government include biopharmaceuticals as one of them. The distinguished entrepreneurs and experts present are leading companies and pioneers in our province’s biopharmaceutical field and are participants in the emerging track of future biopharmaceutical industry. We hope to hear everyone’s ideas and suggestions on how to cultivate and strengthen our province’s biopharmaceutical industry,” Yin Hong straightforwardly addressed the audience, guiding entrepreneurs and scholars to open up discussions and offer advice.

At the forum, the Provincial Department of Industry and Information Technology reported on the development of the province’s biopharmaceutical industry. Leaders and representatives from companies such as Renhe Group, China Resources Jiangzhong, Qingfeng Pharmaceuticals, Fuxiang Pharmaceuticals, Hemei Pharmaceuticals, Jiangxi Biological Products Research Institute, Yichun Dahai Turtle, and Brain Tiger Technology, as well as experts and scholars including Chen Yeguang, Li Hongliang, and Liang Xinmiao, spoke successively. Participants provided insightful analysis of industry trends, combined with their own enterprise realities and research directions, accurately identified issues, and offered sincere and practical suggestions. Yin Hong occasionally interjected to ask questions, engaging in interactive exchanges with entrepreneurs and experts, creating a lively and enthusiastic atmosphere on site.

Yin Hong emphasized that Jiangxi has a solid foundation and advantages for developing the biopharmaceutical industry. It is necessary to accurately grasp industry development trends, based on Jiangxi’s resource endowments and industrial base, concentrate resources to strengthen strengths, address weaknesses, and cultivate new sectors. Efforts should be made to innovate and develop特色, accelerate expanding industry scale and extending产业链, and promote特色化 and差异化 development. The modernization of traditional Chinese medicine (TCM) should be strengthened and optimized, leveraging Jiangxi’s rich TCM resources, deepening the secondary development and成果转化 of classic Chinese medicine formulas, supporting enterprises to accelerate innovation and研发 of改良型新药, actively expanding康养 services and other new formats, further enhancing Jiangxi’s TCM brand. It is crucial to focus on科技创新源头, strengthen the role of企业创新主体, support enterprises in establishing研发中心,中试基地, and验证中心, and focus on tackling frontier fields such as脑机接口,类器官,核医疗, and细胞和基因技术转化, aiming to cultivate new growth points. Industry element support should be reinforced, fully utilizing产业基金引导作用, mobilizing more social and financial capital into the biopharmaceutical industry, further improving flexible人才引进机制, increasing efforts to attract and retain科技领军人才 and urgently needed专业技术人才 in the field, and striving to build a healthy产业生态. Principles of高效规范,公平竞争, and充分开放 should be upheld, actively integrating into and serving the construction of a unified national market, vigorously supporting the clinical application and推广 of innovative products, helping biopharmaceutical companies and products “go global,” and promoting high-quality development of the industry with stronger保障 and better环境.